The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells

Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R ge...

Full description

Saved in:
Bibliographic Details
Published inAsian journal of andrology Vol. 15; no. 6; pp. 753 - 758
Main Authors Wang, Li-Na, Chen, Wei-Wen, Zhang, Ju, Li, Chao-Yang, Liu, Chun-Yan, Xue, Jing, Zhang, Peng-Ju, Jiang, An-Li
Format Journal Article
LanguageEnglish
Published China Medknow Publications & Media Pvt. Ltd 01.11.2013
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer.
AbstractList Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a 1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3′ untranslational region (3′ UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a 1 overexpression or let-7a 1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a 1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3′ UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2 H -tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a 1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a 1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a 1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer.
Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer.
Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer.Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer and progression. In the present study, we demonstrated that the growth inhibitory effect of let-7a1 is directly related to targeting IGF1R gene expression in PC-3 cells. TargetScan predicted three potential target sites (T1, T2 and T3) of let-7a in the 3' untranslational region (3' UTR) of IGF1R mRNA. Real-time PCR, Western blot and luciferase reporter assays were used to detect the effects of let-7a1 overexpression or let-7a1 inhibitor on the IGF1R gene expression in PC-3 cells. The results indicated that let-7a1 could inhibit IGF1R expression by directly targeting the T1 and T2 sites in the 3' UTR of the IGF1R mRNA. We then used RT-PCR, luciferase reporter assays, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) assay, flow cytometry and Hoechst 33342 staining to examine whether let-7a1-mediated inhibition of IGF1R expression also affects the IGF1R-mediated signalling events, including Elk1 activity and c-fos gene expression, proliferation, apoptosis and cell cycle. We demonstrated that let-7a1-mediated IGF1R downregulation was accompanied by attenuation of Elk1 activity and c-fos expression, inhibition of cell proliferation, enhanced apoptosis and cell cycle arrest, and that loss function of let-7a1 via inhibition can upregulate IGF1R accompanied by an increase of Elk1 activity and c-fos expression, thereby enhancing cell proliferation. Altogether, these findings suggest that let-7a may be novel therapeutic candidate for prostate cancer.
Author Chen, Wei-Wen
Zhang, Ju
Jiang, An-Li
Liu, Chun-Yan
Xue, Jing
Wang, Li-Na
Li, Chao-Yang
Zhang, Peng-Ju
Author_xml – sequence: 1
  givenname: Li-Na
  surname: Wang
  fullname: Wang, Li-Na
– sequence: 2
  givenname: Wei-Wen
  surname: Chen
  fullname: Chen, Wei-Wen
– sequence: 3
  givenname: Ju
  surname: Zhang
  fullname: Zhang, Ju
– sequence: 4
  givenname: Chao-Yang
  surname: Li
  fullname: Li, Chao-Yang
– sequence: 5
  givenname: Chun-Yan
  surname: Liu
  fullname: Liu, Chun-Yan
– sequence: 6
  givenname: Jing
  surname: Xue
  fullname: Xue, Jing
– sequence: 7
  givenname: Peng-Ju
  surname: Zhang
  fullname: Zhang, Peng-Ju
– sequence: 8
  givenname: An-Li
  surname: Jiang
  fullname: Jiang, An-Li
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23974362$$D View this record in MEDLINE/PubMed
BookMark eNptkd1rFDEUxYNU7Ic--S4BXyoyaz4nyYtQFlsLRaVU8C1ks3e6WWeTaTKj9b83Q2vR4lMu3F8O59xziPZiioDQS0oWlHD9zm3dghHKF1o8QQdUCdko1rK9OhOim1azb_vosJQtIYxTY56hfcaNErxlB-j2agN4Fy4_neAexkY5ikPchFUYCx7rCm6HDKWEFHHq6qpMfYhNH74Dvs7p57jBnfNjypjiDB6GeTw-Pzull28qjYecyuhGwN5FDxl_WTYce-j78hw97Vxf4MX9e4S-nn64Wn5sLj6fnS9PLhoviKmGlFFetkQB65wRThNJvJaatcR0SrZSd8p4t_aeyBUTlEhlRNdpMHRF1nrNj9D7O91hWu1g7SGO2fV2yGHn8i-bXLD_bmLY2Ov0w3ItBZGiChzfC-R0M0EZ7S6UOYKLkKZiqRCGKcMNrejrR-g2TTnWeDOlmSCa8kq9-tvRg5U_pVTg7R3g6_VKhu4BocTOldtauZ0rt3r2Rx_RPtST18ZqnND_989vbhCtRA
CitedBy_id crossref_primary_10_1038_cddiscovery_2017_28
crossref_primary_10_4103_1008_682X_123680
crossref_primary_10_1155_2015_358125
crossref_primary_10_2174_0122115366253242231020053221
crossref_primary_10_18632_oncotarget_4451
crossref_primary_10_1111_cas_12626
crossref_primary_10_1016_j_canlet_2017_08_011
crossref_primary_10_3390_molecules27030900
crossref_primary_10_1186_s43042_021_00190_9
crossref_primary_10_3390_cimb46120821
crossref_primary_10_1111_andr_12921
crossref_primary_10_1002_jgm_3016
crossref_primary_10_1007_s12032_014_0934_3
crossref_primary_10_1186_s12931_018_0805_0
crossref_primary_10_1016_j_cca_2015_09_022
Cites_doi 10.1080/02841860902874748
10.1038/aja.2012.160
10.3322/caac.20073
10.1158/0008-5472.CAN-04-2446
10.1101/gr.082701.108
10.1677/ERC-08-0084
10.1016/j.molmed.2004.12.005
10.1371/journal.pone.0010147
10.3892/or.2012.2027
10.1016/j.bbrc.2011.11.119
10.1046/j.1464-410X.2003.04061.x
10.1158/0008-5472.CAN-08-1954
10.1016/j.cell.2009.03.047
10.1016/j.urolonc.2006.07.019
10.1016/j.cell.2010.05.017
10.1210/jc.2012-1929
10.1186/bcr3098
10.1158/0008-5472.CAN-04-0637
10.1007/978-3-540-37696-5_4
10.1038/nature06174
10.1007/s10549-010-1168-5
10.4161/cc.7.6.5834
10.1002/hep.23380
10.1101/gad.1640608
10.1089/cbr.2012.1307
10.1016/S0304-3835(03)00159-9
10.1016/j.lungcan.2007.07.013
ContentType Journal Article
Copyright Copyright Nature Publishing Group Nov 2013
Copyright © 2013 SIMM & SJTU 2013 SIMM & SJTU
Copyright_xml – notice: Copyright Nature Publishing Group Nov 2013
– notice: Copyright © 2013 SIMM & SJTU 2013 SIMM & SJTU
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/aja.2013.84
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection (UHCL Subscription)
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
ProQuest One Academic Middle East (New)
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor
EISSN 1745-7262
EndPage 758
ExternalDocumentID PMC3854054
3116500401
23974362
10_1038_aja_2013_84
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-Q-
1OC
23N
2WC
36B
39C
4.4
53G
5GY
5VR
5VS
6J9
70F
7X7
88E
8FI
8FJ
8R4
8R5
AAYXX
ABKZE
ABUWG
ACGFO
ACGFS
ACIHN
AEAQA
AENEX
AFKRA
AFUIB
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
DIK
E3Z
EBS
EJD
EMB
EMOBN
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
HZ~
IAO
IHR
JSO
KQ8
M1P
OK1
P2P
P6G
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
RNTTT
RPM
SV3
TR2
U5O
UKHRP
W3E
~88
-05
-0E
-SE
-S~
.3N
31~
8-1
92F
92I
92M
9D9
9DE
AAOIN
ACXQS
ADJBI
AFBPY
AFZJQ
AJAOE
AZFZN
BFHJK
C1A
CAG
CAJEE
CCEZO
CGR
CHBEP
CIEJG
CO8
COF
CUY
CVF
CW9
DCZOG
ECM
EIF
H13
IHW
INH
INR
IPNFZ
ITC
JUIAU
LH4
LW6
N8Y
NPM
OVD
PJZUB
PPXIY
Q--
Q-4
RIG
RMW
RT5
S..
T8U
TCJ
TEORI
TGQ
U1F
U1G
U5E
WFFXF
~N3
3V.
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c409t-7797c5607e2fa94a8050c8582609f75658f79cadcc05b24105794ff8e91b0d8d3
IEDL.DBID 7X7
ISSN 1008-682X
1745-7262
IngestDate Thu Aug 21 18:20:29 EDT 2025
Thu Jul 10 22:11:57 EDT 2025
Fri Jul 25 23:36:35 EDT 2025
Mon Jul 21 05:57:02 EDT 2025
Sun Jul 06 05:09:19 EDT 2025
Thu Apr 24 22:58:27 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c409t-7797c5607e2fa94a8050c8582609f75658f79cadcc05b24105794ff8e91b0d8d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854054/pdf/aja201384a.pdf
PMID 23974362
PQID 1448240813
PQPubID 28679
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3854054
proquest_miscellaneous_1449279391
proquest_journals_1448240813
pubmed_primary_23974362
crossref_primary_10_1038_aja_2013_84
crossref_citationtrail_10_1038_aja_2013_84
PublicationCentury 2000
PublicationDate 2013-11-01
PublicationDateYYYYMMDD 2013-11-01
PublicationDate_xml – month: 11
  year: 2013
  text: 2013-11-01
  day: 01
PublicationDecade 2010
PublicationPlace China
PublicationPlace_xml – name: China
– name: Shanghai
PublicationTitle Asian journal of andrology
PublicationTitleAlternate Asian J Androl
PublicationYear 2013
Publisher Medknow Publications & Media Pvt. Ltd
Nature Publishing Group
Publisher_xml – name: Medknow Publications & Media Pvt. Ltd
– name: Nature Publishing Group
References Colamaio M (aja201384-bib21) 2012; 97
Martello G (aja201384-bib14) 2010; 141
Pollak M (aja201384-bib5) 2007; 174
LeRoith D (aja201384-bib6) 2003; 195
Nickerson T (aja201384-bib11) 2001; 61
Xiong Y (aja201384-bib17) 2010; 51
Morgan C (aja201384-bib2) 2009; 48
Papatsoris AG (aja201384-bib7) 2005; 11
Valastyan S (aja201384-bib16) 2009; 137
Armstrong AJ (aja201384-bib3) 2005; 12
Park SM (aja201384-bib18) 2008; 22
Zhu ML (aja201384-bib4) 2008; 15
Jemal A (aja201384-bib1) 2010; 60
Ryan CJ (aja201384-bib8) 2007; 25
Kim SJ (aja201384-bib22) 2012; 14
Cai K (aja201384-bib20) 2012; 28
Esquela-Kerscher A (aja201384-bib27) 2008; 7
Dong Q (aja201384-bib25) 2010; 5
Liu Y (aja201384-bib23) 2012; 417
Lu L (aja201384-bib24) 2011; 126
Yang N (aja201384-bib28) 2008; 68
Ma L (aja201384-bib13) 2007; 449
Hellawell GO (aja201384-bib9) 2003; 91
Friedman RC (aja201384-bib12) 2009; 19
Inamura K (aja201384-bib26) 2007; 58
Takamizawa J (aja201384-bib29) 2004; 64
Krueckl SL (aja201384-bib10) 2004; 64
Wang YY (aja201384-bib19) 2013; 28
Amankwah EK (aja201384-bib15) 2013; 15
18344688 - Cell Cycle. 2008 Mar 15;7(6):759-64
17349528 - Urol Oncol. 2007 Mar-Apr;25(2):134-40
20848182 - Breast Cancer Res Treat. 2011 Apr;126(3):687-94
23353719 - Asian J Androl. 2013 Mar;15(2):226-30
19925378 - Acta Oncol. 2009;48(6):882-9
17728006 - Lung Cancer. 2007 Dec;58(3):392-6
20418948 - PLoS One. 2010;5(4):e10147
15574769 - Cancer Res. 2004 Dec 1;64(23):8620-9
23134218 - Cancer Biother Radiopharm. 2013 Mar;28(2):131-7
18667687 - Endocr Relat Cancer. 2008 Dec;15(4):841-9
16018833 - Can J Urol. 2005 Jun;12 Suppl 2:42-7
20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
11507082 - Cancer Res. 2001 Aug 15;61(16):6276-80
18955434 - Genome Res. 2009 Jan;19(1):92-105
12767520 - Cancer Lett. 2003 Jun 10;195(2):127-37
20603000 - Cell. 2010 Jun 25;141(7):1195-207
18381893 - Genes Dev. 2008 Apr 1;22(7):894-907
19524507 - Cell. 2009 Jun 12;137(6):1032-46
17898713 - Nature. 2007 Oct 11;449(7163):682-8
22251626 - Breast Cancer Res. 2012;14(1):R14
22965940 - J Clin Endocrinol Metab. 2012 Nov;97(11):E2168-78
15694866 - Trends Mol Med. 2005 Feb;11(2):52-5
20041405 - Hepatology. 2010 Mar;51(3):836-45
12581018 - BJU Int. 2003 Feb;91(3):271-7
15172979 - Cancer Res. 2004 Jun 1;64(11):3753-6
22155254 - Biochem Biophys Res Commun. 2012 Jan 6;417(1):371-5
22972404 - Oncol Rep. 2012 Dec;28(6):2101-6
17302184 - Recent Results Cancer Res. 2007;174:49-53
19074899 - Cancer Res. 2008 Dec 15;68(24):10307-14
References_xml – volume: 48
  start-page: 822
  year: 2009
  ident: aja201384-bib2
  publication-title: Acta Oncol
  doi: 10.1080/02841860902874748
– volume: 15
  start-page: 226
  year: 2013
  ident: aja201384-bib15
  publication-title: Asian J Androl
  doi: 10.1038/aja.2012.160
– volume: 60
  start-page: 277
  year: 2010
  ident: aja201384-bib1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.20073
– volume: 64
  start-page: 8620
  year: 2004
  ident: aja201384-bib10
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-2446
– volume: 19
  start-page: 92
  year: 2009
  ident: aja201384-bib12
  publication-title: Genome Res
  doi: 10.1101/gr.082701.108
– volume: 15
  start-page: 841
  year: 2008
  ident: aja201384-bib4
  publication-title: Endocr Relat Cancer
  doi: 10.1677/ERC-08-0084
– volume: 12
  start-page: 42
  year: 2005
  ident: aja201384-bib3
  publication-title: Can J Urol
– volume: 11
  start-page: 52
  year: 2005
  ident: aja201384-bib7
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2004.12.005
– volume: 5
  start-page: e10147
  year: 2010
  ident: aja201384-bib25
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0010147
– volume: 28
  start-page: 2101
  year: 2012
  ident: aja201384-bib20
  publication-title: Oncol Rep
  doi: 10.3892/or.2012.2027
– volume: 417
  start-page: 371
  year: 2012
  ident: aja201384-bib23
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2011.11.119
– volume: 91
  start-page: 271
  year: 2003
  ident: aja201384-bib9
  publication-title: BJU Int
  doi: 10.1046/j.1464-410X.2003.04061.x
– volume: 68
  start-page: 10307
  year: 2008
  ident: aja201384-bib28
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-1954
– volume: 137
  start-page: 1032
  year: 2009
  ident: aja201384-bib16
  publication-title: Cell
  doi: 10.1016/j.cell.2009.03.047
– volume: 25
  start-page: 134
  year: 2007
  ident: aja201384-bib8
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2006.07.019
– volume: 61
  start-page: 6276
  year: 2001
  ident: aja201384-bib11
  publication-title: Cancer Res
– volume: 141
  start-page: 1195
  year: 2010
  ident: aja201384-bib14
  publication-title: Cell
  doi: 10.1016/j.cell.2010.05.017
– volume: 97
  start-page: E2168
  year: 2012
  ident: aja201384-bib21
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-1929
– volume: 14
  start-page: R14
  year: 2012
  ident: aja201384-bib22
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3098
– volume: 64
  start-page: 3753
  year: 2004
  ident: aja201384-bib29
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-0637
– volume: 174
  start-page: 49
  year: 2007
  ident: aja201384-bib5
  publication-title: Recent Results Cancer Res
  doi: 10.1007/978-3-540-37696-5_4
– volume: 449
  start-page: 682
  year: 2007
  ident: aja201384-bib13
  publication-title: Nature
  doi: 10.1038/nature06174
– volume: 126
  start-page: 687
  year: 2011
  ident: aja201384-bib24
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-010-1168-5
– volume: 7
  start-page: 759
  year: 2008
  ident: aja201384-bib27
  publication-title: Cell Cycle
  doi: 10.4161/cc.7.6.5834
– volume: 51
  start-page: 836
  year: 2010
  ident: aja201384-bib17
  publication-title: Hepatology
  doi: 10.1002/hep.23380
– volume: 22
  start-page: 894
  year: 2008
  ident: aja201384-bib18
  publication-title: Genes Dev
  doi: 10.1101/gad.1640608
– volume: 28
  start-page: 131
  year: 2013
  ident: aja201384-bib19
  publication-title: Cancer Biother Radiopharm
  doi: 10.1089/cbr.2012.1307
– volume: 195
  start-page: 127
  year: 2003
  ident: aja201384-bib6
  publication-title: Cancer Lett
  doi: 10.1016/S0304-3835(03)00159-9
– volume: 58
  start-page: 392
  year: 2007
  ident: aja201384-bib26
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2007.07.013
– reference: 17302184 - Recent Results Cancer Res. 2007;174:49-53
– reference: 15574769 - Cancer Res. 2004 Dec 1;64(23):8620-9
– reference: 18955434 - Genome Res. 2009 Jan;19(1):92-105
– reference: 19925378 - Acta Oncol. 2009;48(6):882-9
– reference: 12581018 - BJU Int. 2003 Feb;91(3):271-7
– reference: 23353719 - Asian J Androl. 2013 Mar;15(2):226-30
– reference: 15172979 - Cancer Res. 2004 Jun 1;64(11):3753-6
– reference: 19524507 - Cell. 2009 Jun 12;137(6):1032-46
– reference: 16018833 - Can J Urol. 2005 Jun;12 Suppl 2:42-7
– reference: 17349528 - Urol Oncol. 2007 Mar-Apr;25(2):134-40
– reference: 22251626 - Breast Cancer Res. 2012;14(1):R14
– reference: 11507082 - Cancer Res. 2001 Aug 15;61(16):6276-80
– reference: 18667687 - Endocr Relat Cancer. 2008 Dec;15(4):841-9
– reference: 20610543 - CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
– reference: 22155254 - Biochem Biophys Res Commun. 2012 Jan 6;417(1):371-5
– reference: 20418948 - PLoS One. 2010;5(4):e10147
– reference: 19074899 - Cancer Res. 2008 Dec 15;68(24):10307-14
– reference: 18381893 - Genes Dev. 2008 Apr 1;22(7):894-907
– reference: 20041405 - Hepatology. 2010 Mar;51(3):836-45
– reference: 20603000 - Cell. 2010 Jun 25;141(7):1195-207
– reference: 12767520 - Cancer Lett. 2003 Jun 10;195(2):127-37
– reference: 17898713 - Nature. 2007 Oct 11;449(7163):682-8
– reference: 20848182 - Breast Cancer Res Treat. 2011 Apr;126(3):687-94
– reference: 22972404 - Oncol Rep. 2012 Dec;28(6):2101-6
– reference: 22965940 - J Clin Endocrinol Metab. 2012 Nov;97(11):E2168-78
– reference: 17728006 - Lung Cancer. 2007 Dec;58(3):392-6
– reference: 23134218 - Cancer Biother Radiopharm. 2013 Mar;28(2):131-7
– reference: 18344688 - Cell Cycle. 2008 Mar 15;7(6):759-64
– reference: 15694866 - Trends Mol Med. 2005 Feb;11(2):52-5
SSID ssj0023199
Score 2.092387
Snippet Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer...
Reduced microRNA (miRNA) let-7a expression and the activation of insulin-like growth factor-1 receptor (IGF1R) signalling are both involved in prostate cancer...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 753
SubjectTerms 3' Untranslated Regions
Base Sequence
Cell Line, Tumor
DNA Primers
Humans
Male
MicroRNAs - genetics
Original
Prostatic Neoplasms - genetics
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - pathology
Real-Time Polymerase Chain Reaction
Receptor, IGF Type 1 - genetics
RNA, Messenger - genetics
Title The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells
URI https://www.ncbi.nlm.nih.gov/pubmed/23974362
https://www.proquest.com/docview/1448240813
https://www.proquest.com/docview/1449279391
https://pubmed.ncbi.nlm.nih.gov/PMC3854054
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swED62FsZexn7PWxc06MM20Gpbsi09jbY06wYNJayQNyPL0uK2c7Imhf75u7OVtNnG3gw6kPB3uvt0Ot0B7KK9s-jpcp5a7Tl6PMerTKQ8Vw4tcu4TYSigfzLKj8_kt0k2CQG3RUirXNnEzlDXM0sx8j0k_orKcSXi8_wXp65RdLsaWmjch20qXUZaXUxuD1yi7x9J9Wtw8nQS3ufFQu2Zcyo6lIhPSm56pL9o5p_Zknfcz_AxPAq8ke33QD-Be659Cg9Ows34M7hBvNnPZjzaZ4gEL0zCmnbaVM1ywZDjMXcTMl5bNvMsZKDzy-bCsR94El9OWd95hyUMbaCb0-f7r1-GyfgDSrM5PQ5BWsosackVOz3kglHQf_EczoZH3w-PeeiqwC2e5XABhS4s8pzCpd5oaVScxVZleMyItS-Q3ylfaGtqa-OsSikLFLes98rppIprVYsXsNXOWvcKWB47I2PvnUTB3HrjdWVyX7jaSLSbeQQfV3-2tKHkOHW-uCy7q2-hSoShJBhKJSPYXQvP-0ob_xbbWUFUhu22KG-VI4J362HcKPQjTOtm152MTtEa6SSClz2i63lSZGUSXXkExQbWawEqwr050jbTrhi3UMR55ev_L-sNPKT1948Yd2BreXXt3iKbWVaDTmUHsH1wNDodD7qYwG-d6faT
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9QwDLfGkIAXxDdlA4I0JEAKa5t-pA8ITYPjju1OaNqke-vSNOEKo3fbdWL7p_Y3YvfjxgHibW-VYrVN7Ng_x44NsIH6TqOli7ivE8vR4hmehcLnkTSokSPrCUUH-sNR1D8IPo_D8QpcdHdhKK2y04m1os6nms7INxH4SyrH5Yn3s2NOXaMoutq10GjEYsec_0SXbf5u8AH5-9L3ex_3t_u87SrANfoyFcLJJNZo52PjW5UESrqhq2WIMNtNbIz4Rto40SrX2g0zn7IgUWStlSbxMjeXucD3XoPraHhdcvbi8aWDJ5p-lVQvByfrj9v7gK6Qm-obFTnyxFsZLFvAv2Dtn9mZv5m73h243eJUttUI1l1YMeU9uDFsI_H34Qzli_0o9kZbDDnPY-WxopwUWVHNGWJKZs7aDNuSTS1rM975UfHdsK_o-VcT1nT6YR5DnWtm9Phq8Knn7b1GajajyygIg5kmqTxhX7a5YBRkmD-AgytZ74ewWk5L8xhY5BoVuNaaAAkjbZVNMhXZ2OQqQD0dOfCmW9lUtyXOqdPGUVqH2oVMkQ0psSGVgQMbC-JZU9nj32TrHYvSdnvP00thdODFYhg3Ji2EKs30tKZJfNR-iefAo4aji-_4iAIDhA4OxEu8XhBQ0e_lkbKY1MW_hSSMHTz5_289h5v9_eFuujsY7azBLZpLc4FyHVark1PzFJFUlT2rxZfB4VXvl1-G6y9-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+miRNA+let-7a1+inhibits+the+expression+of+insulin-like+growth+factor+1+receptor+%28IGF1R%29+in+prostate+cancer+PC-3+cells&rft.jtitle=Asian+journal+of+andrology&rft.au=Wang%2C+Li-na&rft.au=Chen%2C+Wei-wen&rft.au=Zhang%2C+Ju&rft.au=Li%2C+Chao-yang&rft.date=2013-11-01&rft.pub=Medknow+Publications+%26+Media+Pvt.+Ltd&rft.issn=1008-682X&rft.eissn=1745-7262&rft.volume=15&rft.issue=6&rft.spage=753&rft_id=info:doi/10.1038%2Faja.2013.84&rft.externalDocID=3116500401
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1008-682X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1008-682X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1008-682X&client=summon